Natural pentacyclic triterpenoid from Pristimerin sensitizes p53-deficient tumor to PARP inhibitor by ubiquitination of Chk1

Natural pentacyclic triterpenoid from Pristimerin sensitizes p53-deficient tumor to PARP inhibitor by ubiquitination of Chk1

Inhibition of checkpoint kinase 1 (Chk1) has shown to overcome resistance to poly (ADP-ribose) polymerase (PARP) inhibitors and expand the clinical utility of PARP inhibitors in a broad range of human cancers. Pristimerin, a naturally occurring pentacyclic triterpenoid, has been the focus of intensi...

Full description

Bibliographic Details
Main Authors:	Li Tao, Xiangyu Xia, Shujing Kong, Tingye Wang, Fangtian Fan, Weimin Wang
Format:	Article
Language:	English
Published:	Elsevier 2024-03-01
Series:	Pharmacological Research
Subjects:	PARP inhibitor Pristimerin Chk1 P53-deficient Sensitization
Online Access:	http://www.sciencedirect.com/science/article/pii/S1043661824000355

Similar Items

Pristimerin, a Triterpenoid, Inhibits Tumor Angiogenesis by Targeting VEGFR2 Activation
by: Luyong Zhang, et al.
Published: (2012-06-01)

The multifaceted mechanisms of pristimerin in the treatment of tumors state-of-the-art
by: YingZheng Wang, et al.
Published: (2022-10-01)

Exploring the Synergy between PARP and CHK1 Inhibition in Matched <i>BRCA2</i> Mutant and Corrected Cells
by: Hannah L Smith, et al.
Published: (2020-04-01)

Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review
by: Jia-jun Li, et al.
Published: (2019-07-01)

Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss
by: Dahu Qi, et al.
Published: (2021-01-01)

PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality—An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness
by: Patrycja Gralewska, et al.
Published: (2020-12-01)

Radiation-induced Phosphorylation of Chk1 at S345 is Associated with p53-dependent Cell Cycle Arrest Pathways
by: Hui Tian, et al.
Published: (2002-01-01)

Anti-Tumorigenic Activity of Chrysin from Oroxylum indicum via Non-Genotoxic p53 Activation through the ATM-Chk2 Pathway
by: Mai Nagasaka, et al.
Published: (2018-06-01)

Accurate delivery of pristimerin and paclitaxel by folic acid-linked nano-micelles for enhancing chemosensitivity in cancer therapy
by: Chao Chen, et al.
Published: (2022-11-01)

Protective Effect of Follicle-Stimulating Hormone on DNA Damage of Chicken Follicular Granulosa Cells by Inhibiting CHK2/p53
by: Shuo Zhou, et al.
Published: (2022-04-01)

Pristimerin mediated anticancer effects and sensitization of human skin cancer cells through modulation of MAPK signaling pathways
by: Maha Al-Tamimi, et al.
Published: (2022-12-01)

Beneficial effect of pristimerin against the development of osteoporosis in ovariectomy-induced osteoporosis rats by the RANKL/TRAF6/NF-κB pathway
by: Wei Xu, et al.
Published: (2019-07-01)

PARP-I and p53 expression in Sertoli cell during rat ontogenesis
by: R. Taherian, et al.
Published: (2010-01-01)

Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways
by: Li X, et al.
Published: (2021-01-01)

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
by: Elena Tirrò, et al.
Published: (2019-02-01)

Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
by: Patrycja Gralewska, et al.
Published: (2020-04-01)

Pristimerin Inhibits MMP-9 Expression and Cell Migration Through Attenuating NOX/ROS-Dependent NF-κB Activation in Rat Brain Astrocytes Challenged with LPS
by: Yang CC, et al.
Published: (2020-07-01)

The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous <i>BRCA<sup>MUT</sup></i> and <i>BRCA<sup>WT</sup></i> Ovarian Cancer Cells
by: Patrycja Gralewska, et al.
Published: (2022-06-01)

Pristimerin Suppresses Trophoblast Cell Epithelial–Mesenchymal Transition via miR-542-5p/EGFR Axis
by: Shu C, et al.
Published: (2020-11-01)

The Role of Tumor Protein 53 Mutations in Common Human Cancers and Targeting the Murine Double Minute 2–P53 Interaction for Cancer Therapy
by: Tayebeh Hamzehloie, et al.
Published: (2012-03-01)

Pristimerin Inhibits Prostate Cancer Bone Metastasis by Targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs
by: Shuai Huang, et al.
Published: (2015-08-01)

Lupeol and pristimerin do not inhibit activation of the human sperm CatSper Ca(2+)-channel [version 2; peer review: 2 approved, 1 approved with reservations]
by: Christian Marcus Pedersen, et al.
Published: (2022-08-01)

Phosphoproteomics reveals that cinobufotalin promotes intrahepatic cholangiocarcinoma cell apoptosis by activating the ATM/CHK2/p53 signaling pathway
by: Zhili Xia, et al.
Published: (2022-09-01)

Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin
by: Shi Yandong, et al.
Published: (2012-12-01)

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
by: Nannan Wang, et al.
Published: (2022-08-01)

Pristimerin as a Novel Hepatoprotective Agent Against Experimental Autoimmune Hepatitis
by: Dina S. El-Agamy, et al.
Published: (2018-03-01)

Editorial: Regulation and dysfunction of CSK and CHK
by: Shudong Zhu, et al.
Published: (2023-07-01)

Olaparib-Resistant <i>BRCA2</i><sup>MUT</sup> Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival
by: Łukasz Biegała, et al.
Published: (2023-03-01)

SCFβ‐TrCP ubiquitinates CHK1 in an AMPK‐dependent manner in response to glucose deprivation
by: Ying Ma, et al.
Published: (2019-02-01)

Apoptosis induction and enhanced expression of p53 and PARP genes in the human anaplastic thyroid carcinoma cells line (SW-1736) with Curcumin
by: Khalil khashei varnamkhasti, et al.
Published: (2018-12-01)

Regulation, targets and functions of CHK
by: Shudong Zhu, et al.
Published: (2022-12-01)

Development and Validation of an HPLC-PDA Method for Biologically Active Quinonemethide Triterpenoids Isolated from Maytenus chiapensis
by: Vito Alessandro Taddeo, et al.
Published: (2019-03-01)

UPLC-LTQ-Orbitrap-Based Cell Metabolomics and Network Pharmacology Analysis to Reveal the Potential Antiarthritic Effects of Pristimerin: In Vitro, In Silico and In Vivo Study
by: Mengying Lv, et al.
Published: (2022-09-01)

Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy
by: Salman Ahmed, et al.
Published: (2022-11-01)

Functions and inhibitors of CHK1 in cancer therapy
by: Kailong Jiang, et al.
Published: (2024-06-01)

PARP-1 Expression Influences Cancer Stem Cell Phenotype in Colorectal Cancer Depending on p53
by: Jose D. Puentes-Pardo, et al.
Published: (2023-03-01)

DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer
by: Denis Velic, et al.
Published: (2015-11-01)

PARP-1 and p53 Regulate the Increased Susceptibility to Oxidative Death of Lymphocytes from MCI and AD Patients
by: Felipe Salech, et al.
Published: (2017-10-01)

CHK Methylation Is Elevated in Colon Cancer Cells and Contributes to the Oncogenic Properties
by: Shudong Zhu, et al.
Published: (2021-06-01)

AR phosphorylation and CHK2 kinase activity regulates IR-stabilized AR–CHK2 interaction and prostate cancer survival
by: Huy Q Ta, et al.
Published: (2020-06-01)